Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study

OBJECTIVE: The histological conversion of lung adenocarcinoma (LUAD) into small-cell lung cancer (SCLC) is an important resistance mechanism for epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-resistant LUAD. Anlotinib has been recommended as the third-line treatment for SCLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Jianghua, Leng, Zhaohui, Gu, Hong, Jing, Xiang, Song, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288518/
https://www.ncbi.nlm.nih.gov/pubmed/37361601
http://dx.doi.org/10.3389/fonc.2023.1153131

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10288518/
https://www.ncbi.nlm.nih.gov/pubmed/37361601
http://dx.doi.org/10.3389/fonc.2023.1153131

Ejemplares similares